Literature DB >> 18715153

Secular trends in candidemia-related hospitalization in the United States, 2000-2005.

Marya D Zilberberg1, Andrew F Shorr, Marin H Kollef.   

Abstract

In the United States, from January 1, 2000, through December 31, 2005, the incidence of candidemia-related hospitalization per 100,000 population rose by 52%, from 3.65 to 5.56 cases; and the incidence per 1,000 hospitalizations rose by 49%, from 0.28 to 0.42 cases. The proportion of all candidemia-related hospitalizations in which candidemia was the principal diagnosis remained stable at approximately 14%.

Entities:  

Mesh:

Year:  2008        PMID: 18715153     DOI: 10.1086/591033

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  42 in total

1.  Comparison of BD Bactec Plus Aerobic/F medium to VersaTREK Redox 1 blood culture medium for detection of Candida spp. in seeded blood culture specimens containing therapeutic levels of antifungal agents.

Authors:  Stefan Riedel; Stephen W Eisinger; Lisa Dam; Paul D Stamper; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

2.  When and how to cover for fungal infections in patients with severe sepsis and septic shock.

Authors:  Nicolas Allou; Jerome Allyn; Philippe Montravers
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

3.  Crystal structures of Candida albicans dihydrofolate reductase bound to propargyl-linked antifolates reveal the flexibility of active site loop residues critical for ligand potency and selectivity.

Authors:  Janet L Paulsen; Stephen D Bendel; Amy C Anderson
Journal:  Chem Biol Drug Des       Date:  2011-07-29       Impact factor: 2.817

Review 4.  What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients.

Authors:  Cristóbal León; Luis Ostrosky-Zeichner; Mindy Schuster
Journal:  Intensive Care Med       Date:  2014-04-10       Impact factor: 17.440

5.  Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species.

Authors:  Wiley A Schell; A M Jones; Katyna Borroto-Esoda; Barbara D Alexander
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

6.  In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study.

Authors:  He Wang; Meng Xiao; Sharon C-A Chen; Fanrong Kong; Zi-Yong Sun; Kang Liao; Juan Lu; Hai-Feng Shao; Yan Yan; Hong Fan; Zhi-Dong Hu; Yun-Zhuo Chu; Tie-Shi Hu; Yu-Xing Ni; Gui-Ling Zou; Ying-Chun Xu
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

Review 7.  Persistence and drug tolerance in pathogenic yeast.

Authors:  Rasmus Bojsen; Birgitte Regenberg; Anders Folkesson
Journal:  Curr Genet       Date:  2016-05-19       Impact factor: 3.886

8.  Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study.

Authors:  Marya D Zilberberg; Marin H Kollef; Heather Arnold; Andrew Labelle; Scott T Micek; Smita Kothari; Andrew F Shorr
Journal:  BMC Infect Dis       Date:  2010-06-03       Impact factor: 3.090

9.  Historical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil.

Authors:  Marcos Paulo Wille; Thaís Guimarães; Guilherme Henrique Campos Furtado; Arnaldo Lopes Colombo
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-05       Impact factor: 2.743

10.  Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation.

Authors:  Marya D Zilberberg; Smita Kothari; Andrew F Shorr
Journal:  Crit Care       Date:  2009-06-19       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.